Background. Infection is a serious complication of left ventricular assist device (LVAD) therapy. Published data regarding LVAD-associated infections (LVADIs) are limited by single-center experiences and use of nonstandardized definitions.
With increasing prevalence of heart failure in the United States and limited availability of donor organs [1] , implantable left ventricular assist devices (LVADs) are increasingly being used as a bridge to heart transplantation and as a long-term myocardial surrogate, termed as destination therapy. However, infection is a major complication associated with LVAD therapy, with reported rates ranging from 25% to 80% [2] . Clinical manifestations of LVAD-associated infections (LVADIs) range from local driveline exit site and pocket infections to endovascular infections of the valves or bloodcontacting surfaces of the LVAD, so-called "endocardial" LVAD-related bloodstream infections (BSIs) [1] .
Prior publications that examined different aspects of LVADI have significant limitations in methodology, have small sample sizes, or focused on outdated first-generation pulsatile-flow LVADs. Even the most recently published prospective cohort of LVAD recipients had only 33 infected cases [3] . Moreover, LVADI were often loosely defined, including infections that are not directly related to LVADs, such as pneumonia or urinary tract infections [4] [5] [6] [7] . Similarly, some investigators defined infections by the presence of a positive culture result alone, which failed to distinguish infection from colonization or contamination [4, 8, 9] . Even in the largest LVAD database of 4000 cases-the INTER-MACS registry-LVADIs were loosely defined [10, 11] .
In the current investigation, we report clinical manifestations and management of LVADI from a large, multicenter cohort of patients with continuous-flow (CF) LVADs, using standardized consensus definitions proposed by the International Society of Heart Lung Transplant (ISHLT) [12] .
METHODS
We retrospectively reviewed 247 patients who underwent CF LVAD implantation at Mayo Clinic campuses in Minnesota, Arizona, and Florida between January 2005 and December 2011. These devices included Heartmate II (Thoratec), Jarvik 2000 ( Jarvik Heart), and VentrAssist (Ventracor). Cases were identified from the hospital surgical index. Patients in whom LVADs were not initially implanted at Mayo Clinic, and those with concurrent right ventricular assist devices were excluded to minimize confounders. All patients had consented to the use of their medical records for research purposes. Study proposal was reviewed and approved by the Mayo Foundation Institutional Review Board.
Definitions
LVADIs were classified on the basis of the recent consensus guidelines proposed by the ISHLT [12] . LVADIs were defined as including all infections that occurred in the presence of LVAD that may or may not have been directly attributable to the LVAD therapy but warranted special consideration because of the presence of LVAD. For example, a catheter-related bloodstream infection (CRBSI) that was ultimately deemed not to have seeded the LVAD (and, hence, a non-VAD-related BSI) still required special consideration in the presence of an LVAD. LVADIs, therefore, encompassed all LVAD-specific infections, LVAD-related infections, and non-LVAD-related BSIs. Infections unrelated to LVAD, such as pneumonia and urinary tract infections that did not result in BSI, were excluded. Driveline infection was defined as infection involving the soft tissues surrounding the driveline exit site, typically accompanied by erythema, warmth, and purulent discharge. Pocket infection was defined as infection involving the body cavity that holds the LVAD pump. BSI and CRBSI were defined using Centers for Disease Control and Prevention/National Healthcare Safety Network criteria [13] . Central venous catheter (CVC)-associated BSI was defined as infection involving positive blood cultures in the presence of a CVC without another attributable source of infection that did not meet the strict criteria for CVC-related BSI, such as differential time to positivity or a positive catheter tip culture (>15 colony-forming units). LVAD-associated endocarditis was defined as having clinical evidence of pump and/or cannula infection and the presence of vegetation on echocardiography or a vascular phenomenon as defined by modified Duke criteria [14] . Cases with a high suspicion for device or valvular involvement but no discernible vegetations on echocardiography were classified as pump and/or cannula infection. The classification of all cases was discussed in detail with senior investigators (ie, R. C. W., A. J. W., and M. R. S.).
Each infection episode was defined as a new infection involving a new site and/or new microorganism. The episodes excluded relapses, which were defined as infections that recurred at the same site, were caused by the same organism (with similar susceptibilities) within 1 year of treatment of the original infection, and occurred after clinical resolution of the initial episode of infection. If the susceptibilities of the cultured organism showed new resistance to an antibiotic to which the organism was previously susceptible and with which the patient was treated, this was considered a relapse due to emerging resistance while receiving antibiotic therapy. However, if a patient initially developed a driveline infection that subsequently evolved into a pocket infection, a BSI, and then endocarditis, all involving the same microorganism(s), the most severe of these episodes was used for the purposes of this analysis. Similarly, in patients with multiple relapses of infections, only data from the most-severe episodes were analyzed.
Patients whose episode had >1 organisms, all of which were gram-positive cocci (GPC), were categorized as the GPC group; similarly, patients whose episode had >1 organisms, all of which were gram-negative bacilli (GNB), were categorized as the GNB group. Patients who had multiple organisms from different organism categories were categorized as the mixed group.
Cardiovascular implantable electronic device (CIED) infections were classified as pocket infections or CIED-related endocarditis, as previously described [15] [16] [17] .
The time to onset of infection was defined from the date of implantation to the date of diagnosis of infection or onset of symptoms, if known, whichever came first. The microbiologic etiology of LVADI was defined on the basis of culture results for specimens obtained from sterile sites, such as bloodstream or intraoperative specimens. Superficial swab culture of the driveline site was included only if the patient also met other criteria for driveline infection in accordance with ISHLT definitions. Local infections included driveline and pocket infections, mediastinitis without BSI, and CIED pocket infection. Endovascular infections included pump and/or cannula infections, infective endocarditis, all BSIs, and CIED lead infections. Chronic suppressive antimicrobial therapy was used to suppress LVADI after primary antimicrobial therapy, when the LVAD is deemed to be seeded, and was typically continued indefinitely until death, device explantation, or transfer to hospice care.
Follow-up
In our practice, LVAD coordinators closely follow all patients who undergo LVAD implantation at Mayo Clinic and carefully document in the electronic medical record any additional events that occurred at outside institutions. All patients had a minimum of 6 months of follow-up from the time of LVAD implantation. Driveline exit site care consisted of daily cleansing with chlorhexidine solution via sterile technique and securing of the driveline by an abdominal binder. A major change during the study period was the implementation of the abdominal binder around 2009.
Statistical Analysis
Descriptive statistics for categorical variables are presented as counts and percentages, and those for continuous variables are presented as either means with standard deviations (SD) or medians with interquartile ranges (IQRs), depending on whether the data were skewed. For follow-up events such as all-cause mortality, the event rate at 2 years following the LVAD implantation was estimated using the Kaplan-Meier method. Comparisons of subgroups were made using the Student t test or Wilcoxon rank sum test for continuous variables, as appropriate, and a χ 2 test or Fisher exact test for categorical variables. Statistical analyses were performed using the software package SAS, version 9.2 (SAS Institute, Cary, NC). All statistical tests were 2-sided, and P values of < .05 were considered statistically significant.
RESULTS

Epidemiology and Baseline Characteristics
Based on follow-up of 247 patients who underwent CF LVAD implantation (307.5 total person-years), 101 episodes of LVADI were identified in 78 patients, for an overall incidence of 32.8 cases (95% confidence interval, 26.7-39.9) per 100 person-years of LVAD support. The classification and incidence rates for the different infection types for all 101 episodes of LVADI are summarized in Table 1 . For simplicity and ease of analytical considerations, the rest of the results section is limited to the first episode of infection for each of the 78 patients.
Demographic characteristics, device features, and comorbidities are summarized in Table 2 for the overall group of 78 LVADI patients and for subgroups with systemic (n = 41) and local (n = 37) infections. Heartmate II (94%) was the most commonly used device, with the majority of the driveline exit site tunneled to the right (87%). Of note, 21% of the patients had an active infection and were receiving antibiotic therapy at the time of LVAD implantation.
Clinical Presentation
Driveline infection (47%) was the most common LVADI, followed by BSI, similarly distributed between VAD-and non-VAD-related BSI (24% and 22%, respectively; Table 3 ). The median time from LVAD implantation to the first episode of infection was 4.4 months (IQR, 1.0-13.5 months). Compared with patients who had local infections, patients with endovascular infections appeared to present with infections earlier (median, 1.6 vs 7.1 months after implantation; P = .006) and more frequently with fever (73% vs 19%; P < .001), leukocytosis (71% vs 29%; P < .001), and Systemic inflammatory response syndrome (SIRS) criteria (39% vs 8%; P = .002). Interestingly, all 12 patients who developed driveline trauma subsequently developed driveline infections. The most common sources of BSI were driveline site (49%) and CVC (10%). The driveline was deemed a source when the same organism was cultured from the driveline and the bloodstream.
Microbiology
The distribution of causative pathogens for the first episodes of LVADI in the overall 78 patients and their local versus endovascular infection subgroups are shown in Figure 1 . Staphylococci and nosocomial GNB were the most common causative pathogens.
Management and Outcome
Management interventions for the first episodes of LVADI in 78 patients are summarized in Table 4 . The majority of the patients (76%) were managed without surgical intervention. Only 13% of the patients underwent intraoperative debridement with device retention. The LVAD was eventually removed in 3 patients after failure of conservative management. The overall median duration of antimicrobial therapy was 28.0 days. Patients with local infections were more likely to receive oral antibiotics (57% vs 5%; P < .001), although the duration of antimicrobial therapy was not significantly different between local and endovascular infections (median, 23 vs 33 days; P = .182). The median duration of antimicrobial therapy for driveline infections (n = 36) was 24.5 days (IQR, 13.5-45.5 days). Thirteen patients had 1 or more relapses of LVADI. Of patients who were receiving suppressive antimicrobials, 29% (8/28) developed relapse, compared with 11% (5/45) of those not receiving suppressive antimicrobials. Interestingly, among the 37 patients whose LVADs were not considered seeded (ie, there was no surgical intervention, suppressive antimicrobials, or relapse), the majority had either driveline infections (38%) or non-VAD-related BSI (35%) and received antimicrobials for a median duration of 16 days (IQR, 14-28 days).
The mean follow-up duration (±SD) of LVAD support was 1.6 ±1.1 years. At the 2-year follow-up point from the time of implantation, the rate of all-cause mortality was 43%. Among the 30 patients who received LVAD as a bridge to transplantation, the cumulative incidence of heart transplantation at the 2-year follow-up point was 47%.
Pathogen-Specific LVADI
While small numbers preclude robust statistical analysis between subgroups of LVAD recipients with GPC (n = 31) versus those with GNB (n = 16; Table 5 ), it is interesting to note that patients with GNB infections had fairly high Charlson comorbidity indexes (median, 6). A quarter of those with GNB infections were receiving antibiotics for active infections at the time of LVAD implantation, and they also had high rates of destination therapy (75%) and non-VAD-related BSI (44%). In contrast, many of the GPC patients had VAD-related BSI (39%). A majority of GPC patients were treated with primary antibiotic therapy, primarily parenteral, for >1 month (median, 38.5 days; 84%) and received suppressive oral antimicrobials (65%).
DISCUSSION
Our study is among the largest multicenter cohorts of patients with CF LVADI that uses the new ISHLT definitions and one of the first to describe pathogen-specific features in the clinical presentation of LVADI. Our findings are consistent with previous studies that found that CF LVADs have lower rates of overall (0.32 vs 0.9-3.36 cases per patient-year) and individual types of infections than PF LVADs [4] [5] [6] [18] [19] [20] . Similarly, the microbiology of LVADI appears to be comparable between the 2 types of LVADs, with a predominance of staphylococci, followed by nosocomial gram-negative pathogens such as Pseudomonas, Enterobacter, and Serratia species [4, 20, 21] . However, the rate of fungal infections was lower in our cohort (6.6%), compared with previous PF LVAD studies (16%-23%) [21, 22] . The lower rate of infections in these devices is likely attributable to the fact that CF LVADs require a smaller pump pocket, thinner drivelines, longer driveline tunneling, and simpler mechanics without the need for a mechanical valve. In addition, general increases in provider experience with the management of LVADs and their complications over time may play a role. On the basis of our current analysis, experience from the Mayo Clinic, and data from published literature, we propose a treatment algorithm for the management of LVADI, based on the type and extent of the infection (Figure 2) . The classification of LVADI, although challenging, is integral to the management of these complex infections. The primary decision point in our treatment algorithm is the presence or absence of BSI. Blood cultures should be obtained for all patients with suspected LVADI, even in the absence of systemic signs and symptoms of infection and normal laboratory findings, as systemic manifestations of infection such as fever, leukocytosis, or SIRS criteria were present in only half of the patients with LVADI.
Driveline infections were the most frequent type of LVADI in our cohort and may be difficult to distinguish from local skin irritation due to either driveline trauma or adhesive tape. Interestingly, all reported cases of driveline site trauma in our cohort were followed by driveline infections. Driveline site trauma, a known risk factor for driveline infections [19, 20] , can be minimized by the use of abdominal binder. A positive culture result for a swab specimen from the driveline site must be interpreted with caution because of frequent growth of skin colonizers. Additional imaging, such as ultrasonography or computed tomography, may be warranted if underlying abscess is suspected.
The second most common LVADI in our cohort was BSI. As the most common source of BSI, driveline infections should be treated aggressively to prevent secondary endovascular seeding. A decisive factor in the management of BSI in the setting of an LVAD is whether the LVAD itself is infected. This can be difficult to determine without direct intraoperative culture of the device, which cannot be easily performed. While transesophageal echocardiography (TEE) is recommended in most cases of BSI, vegetations can be missed on TEE because of the reflective internal metal surfaces of the LVAD [26] . TEE should also be considered when blood culture results may be negative because of recent antibiotic use. Despite a lack of vegetations on TEE, LVAD seeding is still a concern if there is (1) failure to clear BSI despite appropriate antibiotic therapy or removal of the suspect catheter in the setting of CRBSI or (2) relapse of BSI after completion of an appropriate antibiotic course. However, the management of each case should be individualized on the basis of clinical judgment.
The optimal duration of antimicrobial therapy for LVADspecific infections is unclear. While localized LVADI may have trended toward shorter courses of antibiotic therapy in our cohort, treatment duration varies with the causative microorganism, the extent and severity of the infection, and the need for surgical debridement [1, 27] . LVAD-related endovascular infections are generally treated with ≥4-week courses of antimicrobials, based on the type of infection (Figure 2) , modeled after the existing guidelines for catheter-related BSI [23] and endocarditis [25] . Any BSI in the setting of LVAD therapy should be treated aggressively, as the same strain has been shown to cause recurrent BSI in LVAD recipients [28] .
While surgical debridement and hardware removal are integral in the management of most prosthesis-related infections, removal of an LVAD cannot be easily accomplished. Complete LVAD removal or exchange is associated with significant morbidity [29] and must be followed by immediate device exchange or heart transplantation. Therefore, device removal is usually reserved as a last resort after lifelong antimicrobial suppression fails, as observed in 3 patients in our cohort. Even after device exchange, suppressive antimicrobial therapy is continued, because the new device is placed in a presumably contaminated operative field.
In general, chronic suppressive antimicrobial therapy is indicated when the LVAD is believed to be seeded. These would include pump and/or cannula infection, endocarditis, pump pocket infection, or persistent or recurrent BSI despite appropriate antibiotic therapy. For patients with just driveline infection or non-VAD-related BSI, chronic suppression is usually not necessary. Failure of antimicrobial suppression may result from the development of drug resistance or nonadherence.
We also noted some interesting pathogen-specific findings in our LVADI study cohort; however, limited number of cases precluded a robust statistical analysis. Staphylococci were the most Bedside debridement 0 (0) 2 (7) Intraoperative debridement with device retention 1 (7) 7 (23) LVAD removal c 1 (7) 0 (0) Other 0 (0) 2 (7) Death common pathogens responsible for LVADI, likely because of multiple surface binding proteins that enhance their ability to attach to prosthetic surfaces [30] . The high prevalence of nosocomial GNB LVADI, especially in destination therapy patients who are not transplant candidate due to poor prognosis, likely reflects the prolonged healthcare exposure that patients with end-stage heart failure experience before LVAD implantation. Because of the high level of drug resistance in nosocomial GNB, some patients with LVAD seeding with GNB required parenteral suppressive therapy.
Our study is retrospective in design and is thus subject to inherent limitations, such as information and recall bias. We rely on objective data and on standardized and reproducible case definitions proposed by the ISHLT to minimize these biases. Mayo Clinic likely has referral bias for sicker and more complex patients; however, patients with end-stage heart failure who require LVADs are typically quite ill and thus are usually managed in tertiary referral centers. Furthermore, despite incorporating patients from geographically diverse Mayo Clinic campuses, our study cohort remained predominantly white. Nevertheless, we believe that our findings should be applicable to LVAD recipients in general. The small sample size also made statistical testing and formal comparisons less feasible. Finally, our proposed treatment algorithm is for general guidance and should be tailored based on individual cases.
In summary, the clinical manifestations and management of LVADI vary based on the extent of infection and the causative pathogens. Understanding these differences is critical in making timely diagnoses and providing appropriate management interventions. We hope that the proposed Mayo Clinic LVADI guideline will be helpful for clinicians managing these complicated infections. Future analysis looking at clinical predictors for LVADI and mortality among LVAD recipients will provide further insight into the management of LVADI.
